Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
A technology for metabolic disorders and compounds, applied in the direction of active ingredients of heterocyclic compounds, metabolic diseases, drug combinations, etc., can solve problems such as errors
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0100] Example 1: Effect of Ertapenem Treatment on Glucose Metabolism Disorders
[0101] In this example, the effect of ertapenem (hereinafter also abbreviated as "DMH") on glucose metabolism disorders was investigated in comparison with metformin (Met), which is known as a first-line drug therapy for the treatment of type 2 diabetes.
[0102] Twelve 7- or 8-week-old db / db mice were randomly divided into 2 groups and injected intraperitoneally (i.p.) with or without ertapenem (DB+DMH group or DB group, respectively) . The treatment of each group is specified in Table 1 below.
[0103] Table 1. Mice were divided into two groups for different treatments
[0104] group use mice deal with DB 6m / m mouse Normal saline, i.p. (10 μL / g body weight / day) DB+DMH 6db / db mice Ertapenem, i.p. (0.41mg / g body weight / day)
[0105] Each mouse was treated intraperitoneally with saline or ertapenem once daily for a total of three weeks. The tests and results...
Embodiment 2
[0128] Example 2: Effect on glucose metabolism disorders after cessation of ertapenem treatment
[0129]To examine the therapeutic effects of ertapenem and metformin (Met) after stopping treatment, eight 8-week-old m / m mice were used as normal controls (G1), and 40 8-week-old db / db mice were randomly Divided into 5 groups (G2 to G6). Each group received a different treatment, as described in Table 5 below.
[0130] Table 5. Mice were divided into 6 groups for different treatments
[0131] group use mice deal with G1 8m / m mouse Normal saline, i.p. (10 μL / g body weight / day) G2 8db / db mice Normal saline, i.p. (10 μL / g body weight / day) G3 8db / db mice Metformin, oral (0.3 mg / g body weight / day) G4 8db / db mice Ertapenem, i.p. (0.1mg / g body weight / day) G5 8db / db mice Ertapenem, i.p. (0.2mg / g body weight / day) G6 8db / db mice Ertapenem, i.p. (0.4mg / g body weight / day)
[0132] Treatment lasted a total of six weeks, after ...
Embodiment 3
[0172] Example 3: Effect on glucose metabolism disorders after cessation of β-lactam compound treatment
[0173] In order to test the effect of β-lactam compounds after drug withdrawal, six 8-week-old m / m mice were used as normal controls (G7), and 42 7-week-old or 8-week-old db / db mice were randomly selected. Divided into 7 groups (G8 to G14). Each group received a different treatment, as described in Table 10 below.
[0174] Table 10. Mice were divided into 8 groups for different treatments
[0175]
[0176] Specifically, each group received the following treatments:
[0177] G7: m / m mice, free to drink water every day, normal saline i.p. (10μL / g body weight);
[0178] G8: db / db mice, free to drink water every day, normal saline i.p. (10μL / g body weight);
[0179] G9: db / db mice, daily ertapenem (DMH) i.p. (0.41mg / g body weight, equivalent to 0.033g / kg for human body);
[0180] G10: db / db mice, daily meropenem hydrate (MER) i.p. (0.205mg / g body weight, equivalent to ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More